| Literature DB >> 31363147 |
Jun-Young Jo1, Seung Ah Ryu2, Jong-Il Kim1, Eun-Ho Lee3, In-Cheol Choi1.
Abstract
We aimed to compare the ability of preoperative estimated glomerular filtration rate (eGFR), calculated using five different equations, to predict adverse renal outcomes after cardiovascular surgery. Cohorts of 4,125 adult patients undergoing elective cardiovascular surgery were evaluated. Preoperative eGFR was calculated using the Cockcroft-Gault, Modification of Diet in Renal Disease (MDRD) II, re-expressed MDRD II, Chronic Kidney Disease Epidemiology Collaboration, and Mayo quadratic (Mayo) equations. The primary outcome was postoperative acute kidney injury (AKI), defined by Kidney Disease: Improving Global Outcomes Definition and Staging criteria based on changes in serum creatinine concentrations within 7 days. The MDRD II and Cockcroft-Gault equations yielded the highest (88.1 ± 26.7 ml/min/1.73 m2) and lowest (79.6 ± 25.5 ml/min/1.73 m2) mean eGFR values, respectively. Multivariable analysis showed that a preoperative decrease in renal function according to all five equations was independently associated with an increased risk of postoperative AKI. The area under the receiver operating characteristics curve for predicting postoperative AKI was highest for the Mayo equation (0.713). Net improvements in reclassification and integrated discrimination were higher for the Mayo equation than for the other equations. The Mayo equation was the most accurate in predicting postoperative AKI in patients undergoing cardiovascular surgery.Entities:
Mesh:
Substances:
Year: 2019 PMID: 31363147 PMCID: PMC6667489 DOI: 10.1038/s41598-019-47559-w
Source DB: PubMed Journal: Sci Rep ISSN: 2045-2322 Impact factor: 4.379
Figure 1Study inclusion/exclusion flow diagram.
Baseline and perioperative characteristics of the patient population.
| Variables | Missing | Total | AKI | No AKI | |
|---|---|---|---|---|---|
| N | 4125 | 1256 | 2869 | ||
| Baseline characteristics | |||||
| Male gender (n, %) | 0 | 2483 (60.2) | 734 (58.4) | 1749 (61.0) | |
| Age (yr) | 0 | 60.6 ± 12.4 | 63.2 ± 11.7 | 59.4 ± 12.5 | <0.001 |
| <40 yr | 272 (6.6) | 51 (4.1) | 221 (7.7) | ||
| 40–49 yr | 446 (10.8) | 106 (8.4) | 340 (11.9) | ||
| 50–59 yr | 1013 (24.6) | 257 (20.5) | 756 (26.4) | ||
| 60–69 yr | 1289 (31.2) | 399 (31.8) | 890(31.0) | ||
| ≥70 yr | 1105 (26.8) | 443 (35.3) | 662 (23.1) | ||
| BMI (kg/m2) | 1 | 24.0 ± 3.3 | 23.9 ± 3.5 | 24.0 ± 3.3 | 0.231 |
| EuroSCORE (logistic) | 0 | 3.6 [1.9–6.8] | 4.5 [2.3–9.0] | 3.1 [1.7–6.0] | <0.001 |
| Haematocrit (%) | 0 | 38.8 [35.2–41.9] | 37.1 [33.3–40.4] | 39.3 [36.0–42.4] | <0.001 |
| Creatinine (mg/dl) | 0 | 0.9 ± 0.5 | 1.0 ± 0.5 | 0.9 ± 0.5 | <0.001 |
| Bilirubin, total (mg/dl) | 1 | 0.8 ± 0.5 | 0.9 ± 0.6 | 0.7 ± 0.4 | <0.001 |
| Albumin (g/dl) | 1 | 3.8 ± 0.5 | 3.6 ± 0.5 | 3.8 ± 0.4 | <0.001 |
| Uric acid (mg/dl) | 2 | 5.7 ± 1.8 | 6.0 ± 2.0 | 5.6 ± 1.7 | <0.001 |
| LVEF (%) | 3 | 60 [54–64] | 59 [52–64] | 60 [55–65] | <0.001 |
| Diabetes mellitus | 0 | 998 (24.2) | 356 (28.3) | 642 (22.4) | <0.001 |
| Hypertension | 0 | 2058 (49.9) | 713 (56.8) | 1345 (46.9) | <0.001 |
| Congestive heart failure | 0 | 316 (7.7) | 129 (10.3) | 187 (6.5) | <0.001 |
| Previous MI | 0 | 253 (6.1) | 69 (5.5) | 184 (6.4) | 0.288 |
| Cerebrovascular disease | 0 | 450 (10.9) | 178 (14.2) | 272 (9.5) | <0.001 |
| PVD | 0 | 475 (11.5) | 190 (15.1) | 285 (9.9) | <0.001 |
| Liver disease | 0 | 222 (5.4) | 85 (6.8) | 137 (4.8) | 0.011 |
| COPD | 0 | 143 (3.5) | 45 (3.6) | 98 (3.4) | 0.859 |
| Dyslipidemia | 0 | 2839 (68.8) | 782 (62.3) | 2057 (71.7) | <0.001 |
| Smoker, current | 0 | 795 (19.3) | 241 (19.2) | 554 (19.3) | 0.961 |
| ACEI or ARB | 0 | 1931 (46.8) | 653 (52.0) | 1278 (44.5) | <0.001 |
| β-blocker | 0 | 1918 (46.5) | 647 (51.5) | 1271 (44.3) | <0.001 |
| CCB | 0 | 1979 (48.0) | 655 (52.1) | 1324 (46.1) | <0.001 |
| Diuretics | 0 | 1719 (41.7) | 591 (47.1) | 1128 (39.3) | <0.001 |
| Insulin | 0 | 417 (10.1) | 175 (13.9) | 242 (8.4) | <0.001 |
| OHA | 0 | 779 (18.9) | 279 (22.2) | 500 (17.4) | <0.001 |
| Aspirin | 0 | 1703 (41.3) | 521 (41.5) | 1182 (41.2) | 0.893 |
| Clopidogrel | 0 | 968 (23.5) | 271 (21.6) | 697 (24.3) | 0.064 |
| Statins | 0 | 2025 (49.1) | 611 (48.6) | 1414 (49.3) | 0.731 |
| Intraoperative data | |||||
| Type of surgery | |||||
| CABG | 0 | 1228 (29.8) | 319 (25.4) | 909 (31.7) | |
| Valve | 0 | 1856 (45.0) | 550 (43.8) | 1306 (45.5) | |
| Aorta | 0 | 264 (6.4) | 107 (8.5) | 157 (5.5) | |
| Combined | 0 | 777 (18.8) | 280 (22.3) | 497 (17.3) | |
| Off-pump surgery | 0 | 1029 (24.9) | 265 (21.1) | 764 (26.6) | |
| Operation time (min) | 0 | 306.6 ± 108.2 | 342.5 ± 134.8 | 290.8 ± 89.8 | <0.001 |
| CPB time (min) | 0 | 110.7 ± 86.5 | 132.6 ± 99.1 | 101.1 ± 78.4 | <0.001 |
| Total crystalloid (L) | 0 | 1.6 [1.2–2.2] | 1.5 [1.1–2.1] | 1.6 [1.2–2.2] | 0.024 |
| Total colloid (L) | 0 | 0.5 [0.5–1.0] | 0.7 [0.5–1.0] | 0.5 [0.5–1.0] | <0.001 |
Data are expressed as number of patients (%), mean ± standard deviation, or median [first-third quartiles].
BMI, body mass index; EuroSCORE, European System for Cardiac Operative Risk Evaluation; LVEF, left ventricle ejection fraction; MI, myocardial infraction; PVD, peripheral vascular disease; COPD, chronic obstructive pulmonary disease; ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; CCB, calcium channel blocker; OHA, oral hypoglycemic agent; CABG, coronary artery bypass grafting; CPB, cardiopulmonary bypass.
Figure 2Distribution of patients by preoperative eGFR according to the five equations. eGFR, estimated glomerular filtration rate; CG, Cockroft-Gault; MDRD, Modification of Diet in Renal Disease; CKD-EPI, Chronic Kidney Disease Epidemiology Collaboration; Mayo, Mayo Clinic Quadratic.
Odds ratio and AUCs for acute kidney injury in preoperative eGFR according to the different equations.
| Equation | Acute kidney injurya | ||||||
|---|---|---|---|---|---|---|---|
| Odds ratio (95% CI)b | AUC (95% CI) | ||||||
| CG | 0.93 (0.90, 0.96) | <0.001 | 0.707 (0.689, 0.725) | ||||
| MDRD II | 0.96 (0.93, 0.99) | 0.003 | 0.704 (0.686, 0.722) | 0.011 | |||
| re-expressed MDRD II | 0.96 (0.93, 0.99) | 0.003 | 0.704 (0.686, 0.722) | 0.011 | 1.000 | ||
| CKD-EPI | 0.91 (0.87, 0.94) | <0.001 | 0.708 (0.690, 0.726) | 0.192 | 0.002 | 0.002 | |
| Mayo | 0.87 (0.83, 0.90) | <0.001 | 0.713 (0.696, 0.731) | <0.001 | <0.001 | <0.001 | <0.001 |
aAdjusted for type of surgery, body mass index, diabetes mellitus, hypertension, dyslipidemia, current smoker, previous myocardial infraction, cerebrovascular disease, peripheral vascular disease, preoperative hematocrit, total bilirubin and albumin levels, left ventricle ejection fraction, preoperative use of β-blocker, calcium channel blocker, insulin, statin, aspirin and clopidogrel.
bFor each 10 U increase in the scale.
cvs. CG; dvs. MDRD II; evs. re-expressed MDRD II; fvs. CKD-EPI.
AUC, area under the receiver-operating characteristic curve; eGFR, estimated glomerular filtration rate; CI, confidence interval; CG, Cockroft-Gault; MDRD, Modification of Diet in Renal Disease; CKD-EPI, Chronic Kidney Disease Epidemiology Collaboration; Mayo, Mayo Clinic Quadratic.
Accuracy of each equation in predicting acute kidney injury after cardiovascular surgery.
| Equation comparison | Acute kidney injury | |||
|---|---|---|---|---|
| NRI% (95% CI) | IDI% (95% CI) | |||
| CG vs MDRD II | −20.7 (−27.5, −14.0) | <0.001 | −0.3 (−0.4, −0.2) | <0.001 |
| CG vs re-expressed MDRD II | −20.7 (−27.5, −14.0) | <0.001 | −0.3 (−0.4, −0.2) | <0.001 |
| CG vs CKD-EPI | 10.1 (3.3, 16.9) | 0.004 | 0.2 (0.1, 0.3) | 0.002 |
| CG vs Mayo | 15.1 (8.3, 21.9) | <0.001 | 0.6 (0.3, 0.8) | <0.001 |
| MDRD II vs re-expressed MDRD II | — | — | — | — |
| MDRD II vs CKD-EPI | 19.1 (12.3, 26.0) | <0.001 | 0.4 (0.3, 0.6) | <0.001 |
| MDRD II vs Mayo | 16.4 (9.6, 23.2) | <0.001 | 0.8 (0.6, 1.1) | <0.001 |
| re-expressed MDRD II vs CKD-EPI | 19.1 (12.3, 26.0) | <0.001 | 0.4 (0.3, 0.6) | <0.001 |
| re-expressed MDRD II vs Mayo | 16.4 (9.6, 23.2) | <0.001 | 0.8 (0.6, 1.1) | <0.001 |
| CKD-EPI vs Mayo | 13.6 (6.7, 20.4) | <0.001 | 0.4 (0.2, 0.6) | <0.001 |
NRI, net reclassification improvement; CI, confidence interval; IDI, integrated discrimination improvement; CG, Cockroft-Gault; MDRD, Modification of Diet in Renal Disease; CKD-EPI, Chronic Kidney Disease Epidemiology Collaboration; Mayo, Mayo Clinic Quadratic.
Postoperative outcomes.
| Outcomes | Total | Group 1 | Group 2 | Group 3 | |
|---|---|---|---|---|---|
| N | 4125 | 2918 | 891 | 316 | |
| Intensive care unit stay (h) | 47.0 [39.9–71.0] | 46.0 [32.0–65.0] | 48.5 [42.5–91.5] | 67.3 [43.5–139.3] | <0.001 |
| Hospital stay (d) | 9.0 [7.0–14.0] | 8.0 [7.0–12.0] | 10.0 [7.0–16.0] | 11.0 [8.0–21.0] | <0.001 |
| Acute kidney injury | 1256 (30.4) | 737 (25.3) | 346 (38.8) | 173 (54.7) | <0.001 |
| KDIGO stage ≥2 | 417 (10.1) | 220 (7.5) | 118 (13.2) | 79 (25.0) | <0.001 |
| Renal replacement therapy | 219 (5.3) | 102 (3.5) | 65 (7.3) | 52 (16.5) | <0.001 |
| In-hospital death | 111 (2.7) | 45 (1.5) | 39 (4.4) | 27 (8.5) | <0.001 |
Data are expressed as number of patients (%) or median [first-third quartiles].
Group 1 = patients with eGFR ≥60 ml/min/1.73 m2 according to all five equations, Group 2 = patients with eGFR ≥60 ml/min/1.73 m2 with one or more equations and/or eGFR <60 ml/min/1.73 m2 depending on the equations used, Group 3 = patients with eGFR <60 ml/min/1.73 m2 according to all five equations. KDIGO, Kidney Disease Improving Global Outcomes classification; eGFR, estimated glomerular filtration rate.